Proactive Investors - Run By Investors For Investors

Redx Pharma poster hails the potential of new class of kidney and liver drug

Highly selective ROCK2 inhibitors are thought to suppress the release of pro-fibrotic factors from kidney mesangial cells
kidney
A new method of treating kidney fibrosis?

Richard Armer, chief scientific officer of Redx Pharma Plc (LON:REDX), believes the company’s new ROCK2 inhibitor drug has the potential to be a “best-in-class agent” for the treatment of fibrotic diseases of the kidney and liver.

His comments came at the conclusion of the American Society of Nephrology’s Kidney Week, in San Diego, California, at which Redx made a poster presentation hailing the potential of using the therapy to tackle chronic kidney disease.

Highly selective ROCK2 inhibitors are thought to suppress the release of pro-fibrotic factors from kidney mesangial cells.

Reduced damage

In an animal model of acute kidney injury, the Redx selective ROCK2 compound reduced damage and the expression of inflammatory and profibrotic genes in the kidney.

In addition, a rat study indicated that the Redx inhibitor avoided cardiovascular side-effects.

"We are pleased that our poster was presented at the high profile American Society of Nephrology Kidney Week,” said Armer.

“We believe our highly selective ROCK2 inhibitors have the potential to be best-in-class agents for the treatment of fibrotic diseases of the kidney such as diabetic nephropathy and of the liver such as non-alcoholic steatohepatitis.

“This is the first publication of our ROCK2 project data and we are delighted that the high quality of our research has been recognised by the ASN."

View full REDX profile View Profile

Redx Pharma Plc Timeline

Related Articles

Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
Once the phase III trial is completed, Futura plans to either sell off the asset or find a partner
September 26 2018
The pharma group expects to dose the first patient in the Phase III trial of its MED2002 erectile dysfunction treatment within the next month
Cancer cells
Tue
The AIM-listed group is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use